Horizon Therapeutics Public - HZNP Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $117.22
Forecasted Upside: 94.08 %
Number of Analysts: 8
Breakdown:
0 Sell Ratings
2 Hold Ratings
6 Buy Ratings
0 Strong Buy Ratings

^$60.40 As of 08/19/2022 01:00 AM ET

▼ -0.81 (-1.32%)

1 month | 3 months | 12 months

Get New Horizon Therapeutics Public Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for HZNP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HZNP

^$117.22

▲ +94.08% Upside Potential

This price target is based on 8 analysts offering 12 month price targets for Horizon Therapeutics Public in the last 3 months. The average price target is $117.22, with a high forecast of $144.00 and a low forecast of $71.00. The average price target represents a 94.08% upside from the last price of $60.40.

Current Consensus is Buy

The current consensus among 8 polled investment analysts is to buy stock in Horizon Therapeutics Public. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
8 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/25/2021

0 strong buy ratings
10 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/26/2021

0 strong buy ratings
10 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

8/24/2021

0 strong buy ratings
9 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

11/22/2021

0 strong buy ratings
9 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

2/20/2022

0 strong buy ratings
7 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

5/21/2022

0 strong buy ratings
7 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

7/20/2022

0 strong buy ratings
6 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

8/19/2022

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
8/4/2022	SVB Leerink	Downgrade	Outperform ➝ Market Perform		Low
8/4/2022	The Goldman Sachs Group	Lower Target	Buy	$164.00 ➝ $144.00	Low
8/4/2022	Morgan Stanley	Lower Target	Overweight	$135.00 ➝ $90.00	N/A
8/4/2022	BMO Capital Markets	Lower Target	Outperform	$145.00 ➝ $117.00	Low
8/4/2022	UBS Group	Downgrade	Buy ➝ Neutral	$137.00 ➝ $71.00	Low
7/8/2022	Oppenheimer	Reiterated Rating	Buy	$140.00	N/A
7/5/2022	UBS Group	Lower Target	Buy	$139.00 ➝ $137.00	N/A
6/13/2022	UBS Group	Initiated Coverage	Buy	$139.00	Low
5/23/2022	SVB Leerink	Initiated Coverage	Market Perform	$95.00	High
4/8/2022	Wells Fargo & Company	Reiterated Rating	Buy	$133.00	Low
3/25/2022	Wells Fargo & Company	Reiterated Rating	Buy	$133.00	Low
3/14/2022	Oppenheimer	Initiated Coverage	Outperform	$140.00	Medium
3/2/2022	Morgan Stanley	Boost Target	Overweight	$135.00 ➝ $140.00	Low
1/26/2022	Piper Sandler	Lower Target		$143.00 ➝ $133.00	Low
12/8/2021	Wells Fargo & Company	Initiated Coverage	Overweight	$137.00	Low
11/18/2021	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$168.00	Low
10/13/2021	Jefferies Financial Group	Initiated Coverage	Buy	$132.00	Low
8/26/2021	Morgan Stanley	Boost Target	Overweight	$103.00 ➝ $135.00	Low
8/24/2021	The Goldman Sachs Group	Boost Target	Neutral	$96.00 ➝ $107.00	Low
8/5/2021	BMO Capital Markets	Boost Target	Outperform	$118.00 ➝ $132.00	Low
8/5/2021	Citigroup	Boost Target	Buy	$117.00 ➝ $121.00	Medium
5/27/2021	Maxim Group	Reiterated Rating	Reduce		High
3/29/2021	Morgan Stanley	Reiterated Rating	Overweight	$103.00	High
3/25/2021	Guggenheim	Boost Target	Buy	$115.00 ➝ $120.00	Low
3/22/2021	Morgan Stanley	Initiated Coverage	Overweight	$103.00	Medium
3/19/2021	Jefferies Financial Group	Reiterated Rating	Buy	$120.00	Low
3/18/2021	Citigroup	Boost Target		$116.00 ➝ $120.00	High
3/17/2021	Stifel Nicolaus	Boost Target	Buy	$110.00 ➝ $125.00	High
3/11/2021	Wolfe Research	Initiated Coverage	Outperform	$107.00	Low
2/17/2021	Jefferies Financial Group	Boost Target		$103.00 ➝ $120.00	Low
2/9/2021	Bank of America	Reiterated Rating	Buy	$100.00	Low
11/3/2020	BMO Capital Markets	Boost Target	Outperform	$105.00 ➝ $110.00	Medium
9/9/2020	JPMorgan Chase & Co.	Initiated Coverage	Overweight	$110.00	High
8/27/2020	Citigroup	Initiated Coverage	Buy	$112.00	Medium
8/17/2020	Bank of America	Boost Target	Buy	$92.00 ➝ $95.00	Low
8/10/2020	Morgan Stanley	Boost Target	Overweight	$70.00 ➝ $90.00	Low
8/6/2020	Guggenheim	Boost Target		$64.00 ➝ $100.00	High
8/6/2020	BMO Capital Markets	Boost Target	Outperform	$70.00 ➝ $105.00	High
8/3/2020	Stifel Nicolaus	Boost Target		$60.00 ➝ $85.00	Low
7/31/2020	Morgan Stanley	Boost Target	Overweight	$50.00 ➝ $70.00	Low
7/22/2020	Piper Sandler	Boost Target	Overweight	$61.00 ➝ $90.00	Low
7/16/2020	Guggenheim	Boost Target		$50.00 ➝ $64.00	Low
6/5/2020	Piper Sandler	Reiterated Rating	Buy	$61.00	Medium
5/29/2020	Stifel Nicolaus	Boost Target		$50.00 ➝ $60.00	High
5/26/2020	Bank of America	Boost Target	Buy	$52.00 ➝ $57.00	Medium
5/21/2020	Piper Sandler	Boost Target	Overweight	$50.00 ➝ $61.00	Medium
5/8/2020	Morgan Stanley	Boost Target	Overweight	$39.00 ➝ $50.00	High
4/28/2020	Jefferies Financial Group	Boost Target	Buy	$47.00 ➝ $51.00	High
4/14/2020	Piper Sandler	Lower Target	Overweight	$46.00 ➝ $44.00	High
4/8/2020	Stifel Nicolaus	Reiterated Rating	Buy	$45.00	Low
4/2/2020	Morgan Stanley	Lower Target	Overweight	$42.00 ➝ $39.00	High
3/23/2020	Bank of America	Lower Target	Buy	$45.00 ➝ $42.00	Low
2/25/2020	Bank of America	Reiterated Rating	Buy	$45.00	High
1/22/2020	BMO Capital Markets	Boost Target	Outperform	$40.00 ➝ $46.00	Low
1/14/2020	JMP Securities	Boost Target	Outperform	$47.00	Medium
1/8/2020	The Goldman Sachs Group	Initiated Coverage	Neutral	$35.00	Low
12/24/2019	Piper Jaffray Companies	Reiterated Rating	Buy	$36.00 ➝ $49.00	Low
12/16/2019	Morgan Stanley	Boost Target	Overweight	$32.00 ➝ $38.00	High
12/16/2019	Jefferies Financial Group	Boost Target	Buy	$35.00 ➝ $40.00	High
12/16/2019	Stifel Nicolaus	Boost Target	Buy	$35.00 ➝ $40.00	High
12/16/2019	BMO Capital Markets	Boost Target	Outperform	$36.00 ➝ $40.00	High
11/8/2019	Cantor Fitzgerald	Boost Target	Overweight	$32.00 ➝ $36.00	Low
9/26/2019	Bank of America	Initiated Coverage	Buy	$34.00	High
9/13/2019	Stifel Nicolaus	Set Target	Buy	$35.00	Low
9/12/2019	Guggenheim	Initiated Coverage	Buy	$36.00	Low
8/26/2019	Piper Jaffray Companies	Set Target	Buy	$33.00	Low
8/14/2019	BMO Capital Markets	Upgrade	Market Perform ➝ Outperform	$29.00 ➝ $36.00	Low
8/7/2019	Cowen	Set Target	Buy	$35.00	Medium
5/8/2019	Mizuho	Set Target	Hold	$27.00	Low
5/1/2019	Citigroup	Upgrade	Neutral ➝ Buy	$21.00 ➝ $32.00	Medium
4/4/2019	Piper Jaffray Companies	Set Target	Buy	$33.00	Low
4/4/2019	BMO Capital Markets	Boost Target	Market Perform	$29.00	Medium
4/2/2019	Cantor Fitzgerald	Boost Target	Overweight ➝ Buy	$26.00 ➝ $32.00	Medium
3/8/2019	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$32.00	Low
3/1/2019	JMP Securities	Boost Target	Outperform	$26.00 ➝ $38.00	High
3/1/2019	Jefferies Financial Group	Boost Target	Positive ➝ Buy	$34.00	High
3/1/2019	Mizuho	Reiterated Rating	Positive ➝ Neutral	$27.00	High
2/28/2019	Cowen	Set Target	Buy	$33.00	Medium
2/7/2019	Mizuho	Reiterated Rating	Hold	$21.00	Low
1/14/2019	Piper Jaffray Companies	Set Target	Buy	$26.00	Low
11/15/2018	Mizuho	Downgrade	Buy ➝ Neutral	$25.00 ➝ $21.00	High
11/7/2018	Mizuho	Reiterated Rating	Buy	$25.00	High
11/1/2018	Stifel Nicolaus	Boost Target	Buy	$25.00 ➝ $35.00	High
10/23/2018	Cowen	Set Target	Buy	$25.00	High
10/18/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$21.00	Low
10/16/2018	Mizuho	Reiterated Rating	Buy		High
10/6/2018	JMP Securities	Set Target	Buy	$22.00	High
10/4/2018	The Goldman Sachs Group	Set Target	Buy	$26.00	Low
9/24/2018	Piper Jaffray Companies	Set Target	Buy	$25.00	Medium
9/17/2018	Piper Jaffray Companies	Set Target	Buy	$25.00	High
9/13/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$21.00	Low
8/17/2018	Morgan Stanley	Boost Target	Equal Weight ➝ Equal Weight	$16.00 ➝ $24.00	Low
8/9/2018	Jefferies Financial Group	Boost Target	Buy ➝ Buy	$21.00 ➝ $23.00	High
8/9/2018	Cowen	Reiterated Rating	Buy	$25.00	High
8/9/2018	Piper Jaffray Companies	Reiterated Rating	Buy	$25.00	High
8/8/2018	Mizuho	Reiterated Rating	Buy	$18.00	High
8/8/2018	Cantor Fitzgerald	Set Target	Buy	$21.00	Low
8/6/2018	BMO Capital Markets	Downgrade	Outperform ➝ Market Perform	$18.00 ➝ $18.00	Low
7/25/2018	Cantor Fitzgerald	Boost Target	Overweight	$21.00	High
6/27/2018	Citigroup	Downgrade	Buy ➝ Neutral		Low
6/18/2018	Stifel Nicolaus	Boost Target	Buy ➝ Buy	$20.00 ➝ $22.00	Low
5/9/2018	Cantor Fitzgerald	Set Target	Buy	$17.00	High
5/7/2018	Mizuho	Reiterated Rating	Buy	$18.00	Low
4/15/2018	Cantor Fitzgerald	Set Target	Buy	$17.00	High
3/14/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$17.00	Low
3/2/2018	Morgan Stanley	Boost Target	Equal Weight ➝ Equal Weight	$14.00 ➝ $16.00	High
3/1/2018	Piper Jaffray Companies	Reiterated Rating	Buy	$22.00	High
3/1/2018	Cowen	Reiterated Rating	Buy	$24.00	High
3/1/2018	UBS Group	Set Target	Buy	$20.00	Medium
2/28/2018	Cantor Fitzgerald	Set Target	Buy	$17.00	Medium
1/12/2018	Mizuho	Upgrade	Neutral ➝ Buy	$12.00 ➝ $18.00	Medium
1/8/2018	Cantor Fitzgerald	Set Target	Buy	$17.00	Medium
12/27/2017	Cantor Fitzgerald	Set Target	Buy	$17.00	Low
12/1/2017	Cantor Fitzgerald	Set Target	Buy	$17.00	Low
11/30/2017	UBS Group	Set Target	Buy	$16.00 ➝ $20.00	High
11/7/2017	Jefferies Financial Group	Boost Target	Buy	$16.00 ➝ $21.00	N/A
10/22/2017	Stifel Nicolaus	Reiterated Rating	Buy	$20.00	N/A
10/15/2017	Piper Jaffray Companies	Set Target	Buy	$18.00	N/A
10/5/2017	Jefferies Financial Group	Reiterated Rating	Buy	$16.00	N/A
9/28/2017	Cowen	Reiterated Rating	Buy		Low
9/28/2017	The Goldman Sachs Group	Initiated Coverage	Buy ➝ Buy	$16.00	Medium
9/27/2017	Jefferies Financial Group	Reiterated Rating	Buy	$16.00	Medium
9/26/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$17.00	Low
9/11/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$17.00	High
9/10/2017	Piper Jaffray Companies	Set Target	Buy	$18.00	Low
8/28/2017	Mizuho	Reiterated Rating	Hold	$9.00 ➝ $12.00	Medium

(Data available from 8/19/2017 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

1 very positive mentions
3 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

1/21/2022

3 very positive mentions
4 positive mentions
2 negative mentions
1 very negative mentions

Mentions as of

2/20/2022

5 very positive mentions
4 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

3/22/2022

2 very positive mentions
4 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

4/21/2022

6 very positive mentions
7 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

5/21/2022

5 very positive mentions
10 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

6/20/2022

1 very positive mentions
5 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

7/20/2022

5 very positive mentions
8 positive mentions
11 negative mentions
1 very negative mentions

Mentions as of

8/19/2022

Current Sentiment

Recent Stories by Sentiment

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.

Today's Range

Now: $60.40

$60.28

$61.41

50 Day Range

MA: $78.08

$60.40

$85.49

52 Week Range

Now: $60.40

$60.28

$120.54

Volume

1,847,698 shs

Average Volume

2,126,700 shs

Market Capitalization

$13.92 billion

P/E Ratio

18.64

Dividend Yield

N/A

Beta

1.12

Frequently Asked Questions

What sell-side analysts currently cover shares of Horizon Therapeutics Public?: The following Wall Street analysts have issued reports on Horizon Therapeutics Public in the last twelve months: BMO Capital Markets, Jefferies Financial Group Inc., Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, StockNews.com, SVB Leerink LLC, The Goldman Sachs Group, Inc., TheStreet, UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for HZNP.
What is the current price target for Horizon Therapeutics Public?: 9 Wall Street analysts have set twelve-month price targets for Horizon Therapeutics Public in the last year. Their average twelve-month price target is $117.22, suggesting a possible upside of 94.1%. The Goldman Sachs Group, Inc. has the highest price target set, predicting HZNP will reach $144.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $71.00 for Horizon Therapeutics Public in the next year.
View the latest price targets for HZNP.
What is the current consensus analyst rating for Horizon Therapeutics Public?: Horizon Therapeutics Public currently has 2 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HZNP will outperform the market and that investors should add to their positions of Horizon Therapeutics Public.
View the latest ratings for HZNP.
What other companies compete with Horizon Therapeutics Public?: Other companies that are similar to Horizon Therapeutics Public include Jazz Pharmaceuticals, Perrigo, Viatris, Teva Pharmaceutical Industries and BioMarin Pharmaceutical. Learn More about companies similar to Horizon Therapeutics Public.
How do I contact Horizon Therapeutics Public's investor relations team?: Horizon Therapeutics Public's physical mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. The biopharmaceutical company's listed phone number is (531) 772-2100 and its investor relations email address is [email protected] The official website for Horizon Therapeutics Public is www.horizontherapeutics.com. Learn More about contacing Horizon Therapeutics Public investor relations.

Horizon Therapeutics Public - HZNP Stock Price Target and Predictions

Analyst Price Target for HZNP

Current Consensus is Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.00 (Hold)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Horizon Therapeutics Public?

What is the current price target for Horizon Therapeutics Public?

What is the current consensus analyst rating for Horizon Therapeutics Public?

What other companies compete with Horizon Therapeutics Public?

How do I contact Horizon Therapeutics Public's investor relations team?